Press release
Products
September 17, 2013

Dr. Stephan Sprenger awarded with the De Bruyne Medal 2013

During Adhesion ´13, the International Conference of the Society for Adhesion and Adhesives, from 4 to 6 September 2013 in York (UK), Dr. Stephan Sprenger was awarded with the De Bruyne Medal.

Norman Adrian de Bruyne PhD, FREng, FRS, was a scientist and pioneer of lightweight construction who had the ability and foresight to translate theoretical scientific insights into practical, commercial applications and products. 1936 he developed the first structural composite for aircraft construction and invented 1942 the first high performance structural aircraft adhesive (Redux®). Sandwich construction with honeycomb core, which he developed during the forties and fifties of last century, are still state-of-the art for lightweight construction, especially in aerospace applications.

Dr. Stephan Sprenger, currently Senior Market Development Manager Composites & Lightweight Construction at Evonik Hanse GmbH (Germany), gained international reputation by his work during the last 20 years. His focus is toughening of thermosetting resins, especially epoxy resins with reactive liquid rubbers, core shell elastomers and SiO2-nanoparticles. These are key raw materials for the formulation of structural adhesives and for fiber-reinforced composites.

Evonik Hanse GmbH is part of the Business Unit Consumer Specialties of Evonik Industries AG and manufactures a variety of raw materials for the adhesives and sealants industry as well as for the composites industry. Toughened epoxy resins, silica nanoparticle containing epoxy resins, block-copolymers, silane-terminated polyurethanes as well as raw materials for silicone adhesives and silicone sealants.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.